Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines

Inclusion Criteria: * Subjects with at least moderate glabellar frown lines at maximum frown using the severity score of at least 2(moderate) on the Facial Wrinkle Scale (4-point FWS) Exclusion Criteria: * Any medical condition (e.g., myasthenia gravis, Lambert-Easton syndrome, amyotrophic lateral sclerosis, etc.) that can affect the neuromuscular function * History of facial nerve paralysis or ptosis * Significant facial asymmetry * Subjects with skin abnormalities such as infection, dermatologic disorders, scars, etc. at potential injection sites * Previous treatment with any serotype of botulinum toxin products within 24 weeks (6 months) prior to Screening or planning to receive treatment with botulinum toxin during the study period * Previous treatment with retinoids (isotretinoin, alitretinoin, etc.)